May 20, 2013
Here are the key earnings that will be moving stocks for the week. Last week there was a mix of better and worse and currently the S&P 500 is showing a good percentage of EPS surprises to the upside but quite concerning revenue Read more
May 13, 2013
Retail will be in the spotlight and all will surely want to watch the gory details of the JC Penny (JCP) report. Other that that, Cisco (CSCO) will be an important measure to see how governments are spending as they receive a good chunk of their revenues from govy contracts.
Watch Deere (DE) as crop prices have fallen and the Read more
May 6, 2013
Another busy week ahead. Not as much as last week and not as important to markets, but there are several companies that will be watched.
First Solar (FSLR) will come out of the gates with some nervous shorts who were recently obliterated after they the company had some solid pre-announcements. Fossil (FOSL) will also be of interest as the company is a good read on the upper end retail. Watch the stock’s reaction to their report as well as companies like Michael Kors (KORS) and Coach (COH).
Disney is one that has been working for investors over time as the company has been able to ramp up several parts of their business to keep earnings growing.
Whole Foods (WFM) has had some difficulty last season as there Read more
May 1, 2013
Something has me wondering. Looking at the initial drop for Allergen (AGN) after the earnings announcement is one thing, but there is definitely more to this story. The conference call started at about 11am for Allergan and within the opening minutes, they dropped the bombshell that caused the stock to plummet.
From the Allergan conference call transcript – (this was toward the beginning of the call at about 11:05 +/-)
Before I provide commentary on the performance of our various businesses, we’d like to provide an update on some important Phase II programs in our R&D portfolio. Regarding dare pin Allergan has completed the initial analysis for the second stage Phase II trial comparing two dozes of DARPin and Lucentis. The data suggests [indiscernible] But do not support directly moving Phase III. Instead we plan to perform additional Phase II work to more completely access safety and efficacy and to guide the Phase III study design. This will likely delay eventual approval by approximately one to two years compared to starting a Phase III program by the end of 2013
The main competition of Allergan’s Macular Degeneration drug is Regeneron (REGN) and this is where the story gets interesting.
Going back to Tuesday afternoon, there was a Read more
April 29, 2013
Yes, another week that will have hundreds of stocks reporting earnings. Over the past couple of weeks there have been some upside surprises that have pushed up prices remarkably and those that disappointing. It appears that there is still some leeway that investors are Read more